Loading company…
Riskpilot
← Back to search
Sign in
Get full access
Wildtype Postbiotics AB
AB
Active
Org 5594125584
Dag Hammarskjöds Väg 36 B
Manufacture of prepared feeds for farm animals · NACE 1091
Est. 2022
0 employees
Watchlist
Share
Overview
Financials
People & ownership
Related companies
Revenue 2024
SEK 1K
EBITDA margin
100.0%
+108% vs 2023
Equity ratio
50.0%
Financial strength
Net profit 2024
SEK 1K
+108% vs 2023
EBITDA — year on year
SEK millions
0M
-0M
-1M
-1M
-1M
0M
2023
0M
0%
2024
Key figures
Annual report 2024
Revenue
SEK 1K
—
EBITDA
SEK 1K
+108%
Net profit
SEK 1K
+108%
Total assets
SEK 26K
+4%
Equity
SEK 13K
+0%
Employees
0
—
Company information
Legal name
Wildtype Postbiotics AB
Org number
5594125584
Legal form
Aktiebolag
NACE code
1091 · Manufacture of prepared feeds for farm animals
Founded
15 december 2022
Share capital
SEK 25 000
Employees
0
VAT registered
No
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Forskning, utveckling, produktion och försäljning av postbiotika som fodertillägg för djur.
Contact
Address
Dag Hammarskjöds Väg 36 B
Email
evelina.vagesjo@ilyapharma.se
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
Visit risika.com
Explore
Companies in Manufacture of prepared feeds for farm animals
Companies in Uppsala
All Sweden companies
Revenue
SEK millions
0M
0M
1M
1M
1M
0M
2023
0M
2024
EBITDA
SEK millions
0M
0M
1M
1M
1M
0M
2023
0M
2024
Income statement
SEK thousands
Item
2023
2024
Revenue
0
1
Staff expenses
—
—
EBITDA
−13
1
Depreciation & amort.
−0
−0
EBIT
−13
1
Net financials
—
—
Profit before tax
−13
1
Tax
−0
−0
Net profit
−13
1
Balance sheet
SEK thousands
Item
2023
2024
Total assets
25
26
Equity
13
13
Long-term debt
0
0
Short-term debt
13
13
Total debt
13
13
Financial ratios
5-year trend
EBITDA margin
100.0%
This company
15.8%
Market median
+533% vs market
2023
2024
Equity ratio
50.0%
This company
38.2%
Market median
+31% vs market
2023
2024
Return on equity
7.7%
This company
18.4%
Market median
-58% vs market
2023
2024
Net profit margin
100.0%
This company
8.1%
Market median
+1135% vs market
2023
2024
Asset turnover
0.04×
This company
1.12×
Market median
-96% vs market
2023
2024
Debt / equity
1.00×
This company
0.62×
Market median
-61% vs market
2023
2024
Annual reports & filings
Annual report 2024
Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
View
PDF
Annual report 2023
Filed via Bolagsverket / SCB · Period 2022-12-01 – 2023-12-31
View
PDF
Management
Actively employed in the business
Name
Role
Member since
Current (1)
LG
Lars Gustaf Kylberg
Audit
Audit
2022
Board of directors
Non-executive oversight
Name
Role
Member since
Current (2)
EW
Evelina Wanda Matilda Vågesjö
Board of Directors
2022
ES
Erik Stefan Roos
Deputy Board Member
2022
Former (1)
OH
Oskar Henrik Gauther Lund
Board of Directors
2022 – 2024
Shareholders
As of last annual report
Shareholder
Type
Ownership
Votes
Since
Ilya Pharma AB (publ)
Company
100%
100%
2024
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive.
Learn more
.
Company hierarchy
Ilya Pharma AB (publ)
Wildtype Postbiotics AB
(this company)
Board network connections
Board members of Wildtype Postbiotics AB also hold positions in
0
other companies.
Person
Role here
Other companies
Lars Gustaf Kylberg
Audit
0 companies
Evelina Wanda Matilda Vågesjö
Board of Directors
0 companies
Oskar Henrik Gauther Lund
Board of Directors
0 companies
Erik Stefan Roos
Deputy Board Member
0 companies